|
Related Party Transactions (Details Textual) (USD $)
|
1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 27, 2012
|
Jan. 31, 2012
|
Dec. 31, 2011
|
Feb. 29, 2012
License, Development and Commercialization Agreement [Member]
Patient
|
Jan. 31, 2012
License, Development and Commercialization Agreement [Member]
Patient
|
Apr. 30, 2010
MSKCC [Member]
|
Dec. 31, 2012
MSKCC [Member]
|
Dec. 31, 2011
MSKCC [Member]
|
Mar. 27, 2012
MSKCC [Member]
Clinical Trial Agreement [Member]
|
Jun. 19, 2011
SKI [Member]
License, Development and Commercialization Agreement [Member]
|
Apr. 30, 2010
SKI [Member]
License, Development and Commercialization Agreement [Member]
|
Dec. 31, 2012
SKI [Member]
License, Development and Commercialization Agreement [Member]
|
Dec. 21, 2012
SKI [Member]
License, Development and Commercialization Agreement [Member]
|
Jan. 31, 2012
Dr. Rosemary Mazanet [Member]
Consulting Services Agreement [Member]
|
Dec. 31, 2012
Dr. Rosemary Mazanet [Member]
Consulting Services Agreement [Member]
|
Aug. 07, 2012
Laidlaw and Company [Member]
Engagement Agreement [Member]
|
Dec. 31, 2012
Laidlaw and Company [Member]
Engagement Agreement [Member]
|
May 09, 2011
Jamess Capital Group LLC [Member]
Transaction management agreement [Member]
|
Dec. 31, 2012
Guagenti & Associates LLC [Member]
|
|
| Related Party Transactions (Textual) | |||||||||||||||||||
| Number of Patients enrolled | 2 | 2 | |||||||||||||||||
| Amount paid under agreement in 2011 | $ 50,000 | ||||||||||||||||||
| Amount paid under agreement in 2012 | 200,000 | ||||||||||||||||||
| Amount paid under agreement in 2013 | 250,000 | ||||||||||||||||||
| Maintenance fees and research payments | 50,000 | ||||||||||||||||||
| Amount paid under agreement | 100,000 | ||||||||||||||||||
| Additional amount due under agreement | 150,000 | ||||||||||||||||||
| Condition for termination of forbearance period | The forbearance period terminated on October 30, 2011, when the Company satisfied a financing condition to the termination of the forbearance period by raising in excess of $3,000.000 in new equity financing. | ||||||||||||||||||
| Termination date of forbearance agreement | Oct. 30, 2011 | Oct. 30, 2011 | |||||||||||||||||
| Minimum new equity financing needed under condition for termination forbearance period | 3,000.000 | ||||||||||||||||||
| Forgiven amount of obligations | 360,000 | ||||||||||||||||||
| Research and development reimbursement payments received from MSKCC | 237,834 | 299,200 | |||||||||||||||||
| Net receivable from MSKCC | 0 | 237,834 | |||||||||||||||||
| Amount paid to each patient after Completing clinical trial | 31,185 | ||||||||||||||||||
| Start-up fee for clinical trial | 79,623 | ||||||||||||||||||
| Due date of start-up fee | Jul. 10, 2012 | ||||||||||||||||||
| Officers' Compensation | 100,000 | ||||||||||||||||||
| Option Exercise Price Range | 0.78 to 1.5 | ||||||||||||||||||
| Term of options | 6 years | 7 years | 7 years | 10 years | |||||||||||||||
| Options received to purchase common stock | 99,900 | ||||||||||||||||||
| Description of receivables of placement agent for services | Placement agent will receive (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent. | ||||||||||||||||||
| Description of warrants receivables by placement | The placement agent or its designees have also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units. | ||||||||||||||||||
| Period of exercise of warrants | Within 6 months of the final closing of the 2012 common stock Offering. | ||||||||||||||||||
| Percentage of solicitation fee | 5.00% | ||||||||||||||||||
| Monthly fee for financial advisory services | 25,000 | ||||||||||||||||||
| Description of additional receivable by placement agent | The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement. | ||||||||||||||||||
| Warrant held by placement agent to purchase common stock | 1,251,015 | ||||||||||||||||||
| Monthly fee received by management firm | 12,500 | ||||||||||||||||||
| Percentage of fully diluted capital stock equal to common stock | 10.00% | ||||||||||||||||||
| Maximum amount of out of pocket expenses | 5,000 | ||||||||||||||||||
| Operating lease monthly amount of rent | 300 | ||||||||||||||||||
| Amount paid to pursuant lease agreement | $ 7,200 | ||||||||||||||||||